Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragments, “Precision,” combined using a proprietary linker with protein toxin payloads “Power.”
Viventia’s most advanced product candidates include ViciniumTM for the treatment of high-grade non-muscle invasive bladder cancer and ProxiniumTM for the treatment of late-stage squamous cell carcinoma of the head and neck.
Viventia has additional early stage products in development that use its TPT technology platform which we expect to begin evaluating in clinical trials in 2016.
Viventia is using fusion protein technology to develop a pipeline of fully biologic molecules combining both the precision targeting of antibody fragments and the tumor cell killing power of protein cytotoxins. Viventia refers to these fully biologic entities as targeted protein therapeutics (TPTs) and is developing them for diseases in oncology.